Anika Therapeutics (ANIK) Q4 2024 earnings summary

Executive summary

• Divested Arthrosurface and Parcus Medical to focus on core hyaluronic acid (HA) products and OA Pain Management, with Integrity, Hyalofast, and Cingal as key platforms.

• Integrity Implant System achieved over 40% sequential growth for three consecutive quarters, with more than 1,000 surgeries performed globally since launch.

• Commercial Channel revenue grew 17% for the year and 25% in Q4, led by Integrity and international OA Pain Management.

• OEM Channel revenue declined 8% for both Q4 and full year, reflecting lower U.S. pricing and competitive pressures.

• Achieved regulatory milestones for Hyalofast (MDR approval, second PMA module filed) and Cingal (FDA Type C meeting held); Integrity clinical study underway.

Financial highlights

• Q4 2024 revenue was $30.6M, up 1% year-over-year; full-year revenue was $119.9M, down 1% from 2023.

• Q4 gross margin was 56% (GAAP), 58% (adjusted); full-year gross margin was 63% (GAAP), 64% (adjusted).

• Q4 operating expenses were $17.8M, down 7% YoY; adjusted EBITDA from continuing operations was $3.6M, down 44% YoY.

• Full-year adjusted EBITDA from continuing operations was $15.5M; adjusted EBITDA margin was 12.9%.

• Ended Q4 with $55.6M in cash and no debt.

Outlook and guidance

• 2025 Commercial Channel revenue expected at $47M–$49.5M (12%–18% growth); OEM Channel expected at $64M–$68.5M (12%–18% decline).

• 2025 adjusted EBITDA margin expected between 8%–10%, reflecting lower OEM pricing and continued R&D investment.

• Hyalofast U.S. launch anticipated by 2026; Integrity clinical study supports further expansion.